AIP gene in pituitary adenoma predisposition

References

• Heaney AP, Melmed S. Molecular targets in pituitary tumours. Nat. Rev. Cancer4, 285–295 (2004).
   PubMed Web of Science ®Google Scholar
• Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr. Relat. Cancer8, 287–305 (2001).
   PubMed Web of Science ®Google Scholar
• Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liège, Belgium. J. Clin. Endocrinol. Metab.91, 4769–4775 (2006).
   PubMed Web of Science ®Google Scholar
• Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr. Rev.26, 615–661 (2005).
   PubMedGoogle Scholar
• Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science276, 404–407 (1997).
   PubMed Web of Science ®Google Scholar
• Kirschner LS, Carney JA, Pack SD et al. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat. Genet.26, 89–92 (2000).
   PubMed Web of Science ®Google Scholar
• Alexander JM. Tumor suppressor loss in pituitary tumors. Brain Pathol.11, 342–355 (2001).
   PubMed Web of Science ®Google Scholar
• Vierimaa O, Georgitsi M, Lehtonen R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science312, 1228–1230 (2006).
   PubMed Web of Science ®Google Scholar
• Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl Acad. Sci. USA103, 15558–15563 (2006).
   PubMed Web of Science ®Google Scholar
• Luccio-Camelo DC, Une KN, Ferreira RE et al. A meiotic recombination in a new isolated familial somatotropinoma kindred. Eur. J. Endocrinol.150, 643–648 (2004).
   Google Scholar
• Daly AF, Jaffrain-Rea ML, Ciccarelli A et al. Clinical characterization of familial isolated pituitary adenomas. J. Clin. Endocrinol. Metab.91, 3316–3323 (2006).
   PubMed Web of Science ®Google Scholar
• De Menis E, Prezant TR. Isolated familial somatotropinomas: clinical features and analysis of the MEN1 gene. Pituitary5, 11–15 (2002).
   Google Scholar
• Verloes A, Stevenaert A, Teh BT, Petrossians P, Beckers A. Familial acromegaly: case report and review of the literature. Pituitary1, 273–277 (1999).
   Google Scholar
• Frohman LA, Eguchi K. Familial acromegaly. Growth Horm. IGF Res.14(Suppl. A), S90–S96 (2004).
   Google Scholar
• Kauppinen-Makelin R, Sane T, Reunanen A et al. A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab.90, 4081–4086 (2005).
   PubMed Web of Science ®Google Scholar
• Daly AF, Vanbellinghen JF, Khoo SK et al. Aryl hydrocarbon receptor interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab. (2007).
   Google Scholar
• Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin. Endocrinol. (Oxf.)66, 499–502 (2007).
   PubMed Web of Science ®Google Scholar
• Toledo RA, Lourenco DM Jr, Liberman B et al. Germline mutation in the aryl hydrocarbon receptor interacting protein (AIP) gene in familial somatotropinoma. J. Clin. Endocrinol. Metab.92(5), 1934–1937 (2007).
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Raitila A, Karhu A et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. Natl Acad. Sci. USA104, 4101–4105 (2007).
   PubMed Web of Science ®Google Scholar
• Yu R, Bonert V, Saporta I, Raffel LJ, Melmed S. Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J. Clin. Endocrinol. Metab.91, 5126–5129 (2006).
   PubMed Web of Science ®Google Scholar
• Barlier A, Vanbellinghen JF, Daly AF et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocrinol. Metab.92(5), 1952–1955 (2007).
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Karhu A, Winqvist R et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br. J. Cancer96, 352–356 (2007).
   Web of Science ®Google Scholar
• Carver LA, Bradfield CA. Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. J. Biol. Chem.272, 11452–11456 (1997).
   PubMed Web of Science ®Google Scholar
• Bolger GB, Peden AH, Steele MR et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J. Biol. Chem.278, 33351–33363 (2003).
   PubMed Web of Science ®Google Scholar
• Sumanasekera WK, Tien ES, Turpey R, Vanden Heuvel JP, Perdew GH. Evidence that peroxisome proliferator-activated receptor α is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2. J. Biol. Chem.278, 4467–4473 (2003).
   PubMed Web of Science ®Google Scholar
• Kang BH, Altieri DC. Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J. Biol. Chem.281, 24721–24727 (2006).
   PubMed Web of Science ®Google Scholar
• Yano M, Terada K, Mori M. AIP is a mitochondrial import mediator that binds to both import receptor Tom20 and preproteins. J. Cell Biol.163, 45–56 (2003).
   Google Scholar
• Froidevaux MS, Berg P, Seugnet I et al. The co-chaperone XAP2 is required for activation of hypothalamic thyrotropin-releasing hormone transcription in vivo. EMBO Rep.7, 1035–1039 (2006).
   PubMed Web of Science ®Google Scholar
• Meyer BK, Perdew GH. Characterization of the AhR–hsp90–XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Biochemistry38, 8907–8917 (1999).
   PubMed Web of Science ®Google Scholar
• Huang G, Elferink CJ. Multiple mechanisms are involved in Ah receptor-mediated cell cycle arrest. Mol. Pharmacol.67, 88–96 (2005).
   PubMed Web of Science ®Google Scholar
• Donangelo I, Marcos HP, Araujo PB et al. Expression of retinoblastoma protein in human growth hormone-secreting pituitary adenomas. Endocr. Pathol.16, 53–62 (2005).
   PubMed Web of Science ®Google Scholar
• Bossis I, Stratakis CA. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology145, 5452–5458 (2004).
   PubMed Web of Science ®Google Scholar
• Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein α-subunit mutations and the role of genomic imprinting. Endocr. Rev.22, 675–705 (2001).
   PubMedGoogle Scholar
• Picard C, Silvy M, Gerard C et al. Gsα overexpression and loss of Gsα imprinting in human somatotroph adenomas: Association with tumor size and response to pharmacologic treatment. Int. J. Cancer (2007) (Epub ahead of print).
   Google Scholar
• Farrell WE, Clayton RN. Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol.21, 174–198 (2000).
   Google Scholar
• Lairmore TC, Piersall LD, DeBenedetti MK et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann. Surg.239, 637–645; discussion 645–637 (2004).
   PubMed Web of Science ®Google Scholar